Angiosoma Stock Performance
| GSTC Stock | USD 0.0001 0.00 0.00% |
The firm shows a Beta (market volatility) of 0.005, which signifies not very significant fluctuations relative to the market. As returns on the market increase, AngioSoma's returns are expected to increase less than the market. However, during the bear market, the loss of holding AngioSoma is expected to be smaller as well. At this point, AngioSoma has a negative expected return of -0.79%. Please make sure to confirm AngioSoma's coefficient of variation, treynor ratio, as well as the relationship between the Treynor Ratio and rate of daily change , to decide if AngioSoma performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days AngioSoma has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain rather sound which may send shares a bit higher in August 2025. The latest tumult may also be a sign of longer-term up-swing for the firm shareholders. ...more
| Begin Period Cash Flow | 5960.00 |
AngioSoma |
AngioSoma Relative Risk vs. Return Landscape
If you would invest 0.02 in AngioSoma on April 28, 2025 and sell it today you would lose (0.01) from holding AngioSoma or give up 50.0% of portfolio value over 90 days. AngioSoma is currently does not generate positive expected returns and assumes 6.2994% risk (volatility on return distribution) over the 90 days horizon. In different words, 56% of pink sheets are less volatile than AngioSoma, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
AngioSoma Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for AngioSoma's investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as AngioSoma, and traders can use it to determine the average amount a AngioSoma's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.126
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | GSTC |
Estimated Market Risk
| 6.3 actual daily | 56 56% of assets are less volatile |
Expected Return
| -0.79 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.13 actual daily | 0 Most of other assets perform better |
Based on monthly moving average AngioSoma is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of AngioSoma by adding AngioSoma to a well-diversified portfolio.
AngioSoma Fundamentals Growth
AngioSoma Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of AngioSoma, and AngioSoma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on AngioSoma Pink Sheet performance.
| Return On Asset | -44.28 | |||
| Current Valuation | 9.39 M | |||
| Shares Outstanding | 770.36 M | |||
| Price To Sales | 78,201 X | |||
| EBITDA | (1.21 M) | |||
| Cash And Equivalents | 12 | |||
| Total Debt | 20 K | |||
| Book Value Per Share | (0) X | |||
| Cash Flow From Operations | (327 K) | |||
| Earnings Per Share | (0.02) X | |||
| Total Asset | 9 | |||
About AngioSoma Performance
By analyzing AngioSoma's fundamental ratios, stakeholders can gain valuable insights into AngioSoma's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if AngioSoma has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if AngioSoma has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
GlobeStar Therapeutics Corporation, a clinical stage pharmaceutical company, focuses on developing a patented formulation of drugs for the treatment of multiple sclerosis and other neurodegenerative diseases. The company was incorporated in 2016 and is based in Richland, Washington. Globestar Therapeutics is traded on OTC Exchange in the United States.Things to note about AngioSoma performance evaluation
Checking the ongoing alerts about AngioSoma for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for AngioSoma help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| AngioSoma generated a negative expected return over the last 90 days | |
| AngioSoma has high historical volatility and very poor performance | |
| AngioSoma has some characteristics of a very speculative penny stock | |
| AngioSoma has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (1.49 M) with loss before overhead, payroll, taxes, and interest of (2.41 K). | |
| AngioSoma currently holds about 12 in cash with (327 K) of positive cash flow from operations. |
- Analyzing AngioSoma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether AngioSoma's stock is overvalued or undervalued compared to its peers.
- Examining AngioSoma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating AngioSoma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of AngioSoma's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of AngioSoma's pink sheet. These opinions can provide insight into AngioSoma's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for AngioSoma Pink Sheet analysis
When running AngioSoma's price analysis, check to measure AngioSoma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AngioSoma is operating at the current time. Most of AngioSoma's value examination focuses on studying past and present price action to predict the probability of AngioSoma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AngioSoma's price. Additionally, you may evaluate how the addition of AngioSoma to your portfolios can decrease your overall portfolio volatility.
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| AI Portfolio Prophet Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. |